Trinity Biotech (TRIB)

• Market cap: $10.9M
• 1 day: 0.00%
• 5 days: -19.23%
• 1 month: -18.06%
• 3 months: -39.99%
• 6 months: -51.28%
• Year to date: -39.99%
• 1 year: -70.77%
• 5 years: -88.05%
• 10 years: -99.41%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Employees: 380

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

21% more funds holding

Funds holding: 19 [Q3] → 23 (+4) [Q4]

0.46% less ownership

Funds ownership: 1.18% [Q3] → 0.72% (-0.46%) [Q4]

22% less capital invested

Capital invested by funds: $2.95M [Q3] → $2.3M (-$646K) [Q4]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3